Top Arecoline Secrets
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine To guage multiple intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Primary trial targets were To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyositis people, ev